Ambiq Launches Two New Edge AI Runtime Solutions
Addressing Critical Edge AI Challenges
As AI workloads increasingly migrate to edge devices, developers face growing pressure to deliver high performance within strict power budgets. Traditional AI frameworks often struggle in ultra-low-power scenarios, making it difficult to deploy sophisticated AI models in battery-powered devices, such as wearables, hearables, IoT sensors, and industrial monitors.
Ambiq's new runtime solutions expand its growing portfolio of developer-centric tools, designed to help engineers unlock the full potential of Apollo SoCs. HeliosRT and HeliosAOT offer flexible, high-performance deployment options for edge AI across a wide range of applications, from digital health and smart homes to industrial automation and beyond.
HeliosRT: Power-Optimized LiteRT
HeliosRT is a performance-enhanced implementation of LiteRT (formerly TensorFlow Lite for Microcontrollers) that is tailored for energy-constrained environments. Fully compatible with existing TensorFlow workflows, HeliosRT introduces key improvements:
HeliosAOT: Compiling LiteRT to Optimized C Code
HeliosAOT introduces a ground-up, ahead-of-time compiler that transforms TensorFlow Lite models directly into embedded C code for edge AI deployment. This innovative approach offers runtime-level, or better, performance with additional benefits:
'The intersection of developer experience and power efficiency is our north star,' said Carlos Morales, VP of AI at Ambiq. 'HeliosRT and HeliosAOT are designed to integrate seamlessly with existing AI development pipelines while delivering the performance and efficiency gains that edge applications demand. We believe this is a major step forward in making sophisticated AI truly ubiquitous.'
Powered by SPOT® and Real-World Success
Both Helios solutions are built on Ambiq's patented Sub-threshold Power Optimized Technology (SPOT), which is the foundation behind over 270 million devices deployed worldwide. Leveraging years of hardware-software co-design, these tools deliver measurable performance gains and streamlined deployment for developers targeting the edge.
Availability
Both solutions are supported with robust documentation, ready-to-use examples, and dedicated engineering assistance for Ambiq customers.
About Ambiq
Ambiq's mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. Ambiq enables its customers to deliver AI compute at the edge where power consumption challenges are the most profound. Ambiq's technology innovations, built on the patented and proprietary sub-threshold power optimized technology (SPOT), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. Ambiq has powered over 270 million devices to date. For more information, visit
www.ambiq.com
.
Contact
Charlene Wan
VP of Corporate Marketing and Investor Relations
cwan@ambiq.com
+1.512.879.2850
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5265c973-0202-4e66-b9df-47fff71759ea
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 minutes ago
- Business Wire
OpenX Fuels Continued Commercial Growth With Expanded Leadership Across Buyer Development and Marketing
BUSINESS WIRE)--OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced the promotions of Stacy Bohrer to Senior Vice President of Buyer Development and Amanda Forrester to Senior Vice President of Marketing and Communications, reinforcing the company's commitment to commercial momentum and partner-centric product innovation. OpenX Technologies, Inc., one of the world's leading omnichannel supply-side platforms, today announced the promotions of Stacy Bohrer to Senior Vice President, Buyer Development, and Amanda Forrester to Senior Vice President, Marketing and Communications. These leadership elevations follow a strong 2024 and continued growth in early 2025, driven by the success of OpenXSelect — the company's advertiser-focused curation and supply-side targeting platform. Over the past year, OpenX has added more than 200 net new brands and seen a surge in engagement across curated deals and targeting tools, underscoring the company's commercial momentum. Today, OpenX has approximately 400 employees and will grow its commercial team by more than 20% in the second half of 2025, with over one-third of that expansion taking place in international markets. This growth will strengthen the company's ability to serve brands and independent agencies, respond quickly to buyer needs, and deliver the market's most intuitive, high-performing platform. Bohrer has been a key architect of that progress, growing strategic partnerships across holding companies, independent agencies, and direct marketers. In addition to scaling the sales organization, she established a high-performing account management function to deliver best-in-class service and client satisfaction. In her expanded role, Bohrer will oversee all buyer development efforts across the Americas, including OpenX's newly opened office in Mexico City, strengthening the company's global footprint and enhancing its service across key growth markets. 'Stacy's impact has been nothing short of transformational,' said Matt Sattel, Chief Revenue Officer at OpenX. 'She knows how to build high-performing teams that deliver for clients, and she does it with relentless focus and strategic clarity. As we double down on our buyer relationships and expand our presence across the Americas, Stacy's leadership will be key to accelerating growth and deepening trust with partners who are looking for smarter, faster, and more effective ways to buy media.' 'We're no longer just a pipe: The supply side is now delivering critical product functionality that drives performance for marketers and agencies,' said Stacy Bohrer, SVP of Buyer Development at OpenX. 'Clients deserve a supply partner they can trust — one that is transparent, collaborative, and invested in delivering on outcomes. That's where I'll be focused: deepening partnerships, accelerating innovation, and delivering measurable results.' Forrester, a seasoned and product-first marketing leader, has helped align the voice of the customer with product strategy while refining OpenX's market positioning. Her work has sharpened the company's position in the marketplace, informed the roadmap, and strengthened collaboration across marketing, product, sales, and engineering. Under her leadership, marketing has become a growth engine, shaping narratives, accelerating new product initiatives, and expanding OpenX's global impact in key markets including the UK, Australia, France, Germany, and Japan. 'Placing the customer's voice at the center of our business has been essential to guiding both product and marketing strategy while aligning sales, events, and communications under a unified vision. I'm energized to carry that perspective into every facet of our work, ensuring we remain solutions-driven and customer-led,' said Amanda Forrester, SVP Marketing and Communications. 'With powerful technology and rich insights at our disposal, the supply side is uniquely positioned to shape what's next — and there's never been a more exciting time to lead that transformation.' 'Stacy and Amanda represent the best of OpenX: curious, innovative, customer-obsessed, and deeply collaborative,' said John Gentry, CEO of OpenX. 'Their influence goes beyond sales and marketing — they help foster the kind of effective, driven, and inclusive culture that makes OpenX a great place to work and accelerates innovation and execution.' About OpenX OpenX is an independent omnichannel supply-side platform (SSP) and a global leader in supply-side targeting, transparency, and sustainability. Through its 100% cloud-based tech stack, OpenX powers advertising across CTV, app, mobile web, and desktop, enabling publishers to deliver marketers with improved performance and dynamic future-proofed solutions. With a 15-year track record of programmatic innovation, OpenX is a direct and trusted partner of the world's largest publishers, working with more than 150,000 premium publisher domains and over 100,000 advertisers. As the market leader in sustainability, OpenX was the first adtech company to be certified as CarbonNeutral™ and third-party verified for achieving its SBTi Net-Zero targets. Learn more at
Business Wire
4 minutes ago
- Business Wire
ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer
NORFOLK, Va.--(BUSINESS WIRE)-- ReAlta Life Sciences, Inc. ('ReAlta' or the 'Company'), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced the appointment of Ellen Lubman, MBA as Chief Business Officer. In this role, Ms. Lubman will oversee business development, capital formation and corporate strategy. 'Ellen is a highly respected executive with a strong track record of building partnerships, raising capital, and developing successful corporate strategies for biotech and pharmaceutical companies,' said David Marek, Chief Executive Officer of ReAlta. 'We are excited to welcome Ellen at such a pivotal moment for our business with all three clinical programs reading out this year. Her deep strategic and transactional expertise strengthens our team, and she will play a key leadership role as we forge partnerships with pharmaceutical companies and investors alike to advance our transformative therapies for patients across numerous severe inflammatory diseases with high unmet need.' 'I am thrilled to join ReAlta and build on the company's accomplishments in developing the EPICC platform and its lead asset pegtarazimod, which has the potential for clarity this year on a path to approval in hypoxic ischemic encephalopathy (HIE), a devastating disease where no pharmacologic treatment exists,' said Ms. Lubman. 'It is a privilege to contribute to the advancement of this differentiated approach to support the delivery of innovative therapies treating neuroinflammation in newborns with HIE, acute graft-versus-host disease (aGvHD), and acute Chronic Obstructive Pulmonary Disease (COPD).' Ms. Lubman brings seasoned leadership and broad experience across small to large-cap private and public biopharmaceutical companies, with a strong track record in strategic, transactional, and operational roles to ReAlta. She joins ReAlta from Werewolf Therapeutics where she was Chief Business Officer, ushering the company through multiple financings, including an Initial Public Offering, as well as business development transactions. Prior to Werewolf, she was Chief Business Officer of Impel Pharmaceuticals and Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company's diverse pipeline of therapeutics in a variety of disease areas. Ms. Lubman has held numerous other executive and leadership roles at Kadmon Pharmaceuticals, Bristol Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank, and Abbott Labs. She serves on the Board of Directors of Reunion Neuroscience and Cytovation ASA and is a Strategic Advisor to Two Bear Capital. Ms. Lubman earned her M.B.A. from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. About ReAlta Life Sciences ReAlta Life Sciences, Inc. is a clinical mid-stage biopharmaceutical company dedicated to addressing life threatening rare and acute inflammatory diseases by rebalancing the inflammatory response. The Company's EPICC peptide platform leverages discoveries from the human astrovirus (HAstV-1), which uniquely inhibits components of the innate immune system. ReAlta's therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs). The Company's lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that causes brain damage and high mortality in oxygen-deprived newborns; Orphan Drug Designation by the European Medicines Agency for HIE; FDA Orphan Drug and Fast Track Designations for acute graft-versus-host disease (aGvHD) associated with bone marrow and stem cell transplants; and FDA IND clearance for acute exacerbations of chronic obstructive pulmonary disease (COPD). Founded in 2018, ReAlta operates in Norfolk, Virginia and Aguadilla, Puerto Rico. For more information, please visit
Business Wire
4 minutes ago
- Business Wire
The Beachbody Company, Inc. Announces Second Quarter 2025 Earnings Release Date, Conference Call and Webcast
EL SEGUNDO, Calif.--(BUSINESS WIRE)--The Beachbody Company, Inc. (NYSE: BODI) ('BODi' or the 'Company'), a leading fitness and nutrition company, will release its second quarter 2025 results on Tuesday, August 5, 2025, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results. The toll-free dial-in for the conference call is (833) 470-1428 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference ID is 327708. A live webcast of the conference call will also be available on the Company's investor relations website at For those unable to participate in the conference call, a replay will be available after the conclusion of the call on August 5, 2025, through August 12, 2025. The toll-free replay dial-in number is (866) 813-9403 (U.S & Canada). The replay passcode is 843571. About BODi and The Beachbody Company, Inc. Originally known as Beachbody, BODi has been innovating structured step-by-step home fitness and nutrition programs for 26 years such as P90X, Insanity, and 21-Day Fix, plus the first premium superfood nutrition supplement, Shakeology. Since its inception in 1999, BODi has helped over 30 million customers pursue extraordinary life-changing results. The BODi community represents millions of people helping each other stay accountable to goals of healthy weight loss, improved strength and energy, and resilient mental and physical well-being. For more information, please visit
